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the CC BY-NC-ND license (http://creatiAbstract Background/purpose: The incidence rate of oral and pharyngeal cancers in Taiwan
has increased gradually over the past few decades. The standard treatment strategy for oral
and pharyngeal cancers includes surgery or radiotherapy, with concurrent chemotherapy in
certain types of tumors. Unfortunately, in-field recurrence is sometimes inexorable. Further-
more, re-irradiation of the recurrence site may cause severe complications due to the toler-
ance of normal tissue to radiation therapy. One fatal complication is carotid blowout
syndrome (CBS). Boron neutron capture therapy (BNCT) is a new modality of radiation therapy,
which is also mentioned as targeted radiotherapy. It is a feasible treatment that has the po-
tential to spare normal tissue from being damaged by irradiation while simultaneously treating
the primary tumor. In this presentation, we will share our experience with BNCT in treating
recurrent head and neck cancers, as well as the prevention and management of CBS.ral and Maxillofacial Surgery, Department of Stomatology, Taipei Veterans General Hospital, No. 201,
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+ MODELMaterials and methods: We evaluated 4 patients with head and neck cancers treated by BNCT
in Taiwan. All patients had undergone surgery previously and had received postoperative con-
current chemoradiotherapy.
Results: The 4 patients in this study were diagnosed with head and neck malignancies. The me-
dian follow-up period after the first course of BNCT was 15.1 months. After BNCT, 2 patients
developed impending CBS, and 1 of them died. The remaining 3 patients survived until the last
date of follow-up.
Conclusion: Pre-BNCT carotid artery evaluation through computed tomography angiography
and early intervention if necessary is crucial when treating patients with recurrent head and
neck cancers by BNCT.
ª 2021 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier
B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).Introduction
The incidence of oral and pharyngeal cancers in Taiwan has
increased gradually over the past few decades. Annual
newly diagnosed cases increased from 5458 in 2007 to 7797
in 2017, based on data released by the Ministry of Health
and Welfare in Taiwan.1 The standard treatment for oral
and pharyngeal cancers includes surgery for early-stage or
locally advanced tumors. Definitive radiotherapy with
concurrent chemotherapy is also considered in certain
types of tumors. For patients undergoing surgery, post-
operative radiotherapy is also indicated if the pathology
shows positive surgical margins, positive lymph node me-
tastases with extranodal extension, or other adverse fea-
tures if a higher rate of recurrence is expected.2 Therefore,
radiotherapy plays an irreplaceable role in the treatment of
oral and pharyngeal cancers.
Boron neutron capture therapy (BNCT) is a new modality
of radiation therapy. It is a binary treatment modality that
includes intravenous injection of a boron-containing drug
and neutron irradiation of the tumor site after adequate
uptake of the boron-containing drug by the tumor.
Following a neutron fissure reaction due to neutron irradi-
ation of the boron-10 particle, an a-particle and a
rebounding lithium particle are ejected. Based on previous
studies, the length of the a-particle, which is the main
source of radiation damage, is approximately 9 mm.3 As we
know, the average diameter of a single cell is approxi-
mately 10 mm. We speculate that the radiation damage by
BNCT is limited to the cells with a high boron-containing-
drug uptake and that nearby normal tissue damage is
minimized.
As mentioned above, most patients with head and neck
cancers receive radiation therapy. Unfortunately, in-field
recurrence is sometimes inexorable. Re-irradiation of the
recurrence site may cause severe complications due to the
normal tissue dose limitation caused by radiation therapy.
One fatal complication is carotid blowout syndrome (CBS).
Even though the incidence rate is relatively low for re-
irradiated head and neck cancers (around 2e10%),4,5 it is
still one of the priority issues for which medical experts
should take extra caution when making decisions for
salvage treatment of recurrent tumors due to its high
mortality rate. Previous studies have shown CBS related2
mortality to range from 3% to 50%,5e7 which is a wide range,
considering the variable approaches and techniques avail-
able.8 Thus, it has been a difficult issue regarding salvage
treatment for recurrent head and neck cancers. BNCT,
which was described in the previous paragraph, is a feasible
treatment modality that has the potential to spare normal
tissues from being damaged by irradiation, while simulta-
neously treating the primary tumor. In this article, we
investigate the factors related to post-BNCT CBS and urge
the importance of pre-BNCT carotid evaluation and inter-
vention when necessary.Materials and methods
Following the first treatment of BNCT in Taiwan, Taipei
Veterans General Hospital (TPEVGH) started treating using
a Tsing-Hua Open Pool Reactor (THOR) as a reliable source
of neutrons, which are required for the BNCT treatment.9
As CBS is a life-threatening event that is highly related to
previous treatment, computed tomography angiography
(CTA) was performed for carotid artery evaluation, espe-
cially for patients with a history of radiotherapy. The type
of CBS is categorized based on previous articles.10 Threat-
ened CBS (Type 1) is described with carotid artery exposure
with image studies, or with areas of arterial wall disruption
with vascular studies. Impending CBS (Type 2) involves
limited bleeding episodes that can be controlled tempo-
rarily by applying pressure. Carotid system hemorrhage
(Type 3) implies active bleeding or carotid rupture, which is
crucial if immediate vascular intervention is not performed.
Pre-BNCT preparation
BNCT is a binary method, with a boron-10 containing drug
administered and ideally accumulated in the tumor. Ther-
mal neutrons and epithermal neutrons produced by the
nuclear reactor will then irradiate the tumor site. The
tumor eradication effect of BNCT is mainly achieved by the
boron capture reaction, as boron-10 nuclear fission gener-
ates an a-particle (4He) and recoiling lithium (7Li), with
energy of about 2.33 MeV deposited. Borono-L-phenylala-
nine (BPA), a boron-containing drug widely used in the field
of BNCT, was designed to be the boron-10 carrier in this
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structure being similar to that of L-tyrosine, it can be
massively absorbed by the tumor through the L-type amino
acid transporter 1, which is highly expressed on the surface
of human tumors.
All patients received 4-borono-2-18F-fluoro-phenylala-
nine-positron emission tomography (FBPA-PET) before
salvage BNCT was performed (Fig. 1). By binding radioiso-
tope fluorine-18 to BPA, the distribution of F-BPA can be
tracked, and thus we were able to calculate the relative
concentration between the tumor, blood, and normal tissue
by the standard uptake value (SUV).
BNCT on-site treatment schedule
On the day of BNCT, the patient will be sent to the National
Tsing Hua University Open Pool Reactor (THOR). THOR is a
uranium-235 circulating pool reactor located in the com-
pass of Tsing Hua University. The standard power of THOR isFigure 1 4-borono-2-18F-fluoro-phenylalanine-positron emissio
yglucose (FDG)-PET image, the normal brain has fewer uptake of th
and normal tissue. Tumor to normal tissue (TN) ratio and tumor to b
Tsing Hua University Open Pool Reactor (THOR) planning system w
and treatment angle we define.
3
approximately 2.0 MW, and the standard neutron flux meets
the requirements of BNCT (>109 n/cm2s). Before irradia-
tion, the patient will receive continuous intravenous BPA
infusion. The infusion rate is based on the experience of
several Japanese studies,11 which is 180mg/kg of body
weight per hour for 2 h before irradiation, and continued
infusion with 90mg/kg of body weight per hour during the
irradiation time, around 30min. With this infusion strategy,
the serum BPA concentration likely ranges between 25 and
35 ppm.
All patients in our study were followed up until August
31, 2020, or the date the patient died. In our study, the
primary outcome was whether the patient developed CBS,
with impending CBS categorized as a positive finding.
Patients
We evaluated 4 patients with head and neck cancers
treated by BNCT in Taiwan. The patient profile isn tomography (FBPA-PET) image. Compared to fluorodeox-
e radioactive 18-F, which helps distinguish between the tumor
lood (TB) ratio will be obtained by this study, and the National
ill calculate the dose distribution based on the dose constraint
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previously and had received postoperative concurrent
chemoradiotherapy. The pathology of all four primary tu-
mors was squamous cell carcinoma. Further FBPA evalua-
tion for calculation of tumor-to-blood ratio (TB ratio) and
tumor-to-normal tissue ratio (TN ratio) was performed at
the Department of Nuclear Medicine in TPEVGH. BNCT
treatment was approved by the institutional review board
(IRB) of TPEVGH and Taiwan’s Food and Drug Administration
(TFDA). A multidisciplinary discussion was conducted to
evaluate the potential risks and benefits of the patients
receiving BNCT.
Results
The 4 patients in this study were diagnosed with head and
neck malignancies. The median follow-up period after the
first course of BNCT was 15.1 months (range, 5.6e36
months). After BNCT, 2 patients developed impending CBS,
and 1 of them died (Fig. 2). The remaining 3 patients sur-
vived until the last date of follow-up (Table 4).
The second patient received 2 courses of external beam
radiotherapy and 2 courses of BNCT. His history of head and
neck cancer goes back to January 2011, when right cheek
squamous cell carcinoma was discovered. A second primary
diagnosis of right buccal squamous cell carcinoma was
made in 2012, and a third primary diagnosis of lower gingiva
squamous cell carcinoma in 2016. He had received two
courses of concurrent chemoradiotherapy, first for the
second primary right buccal tumor with 6600 cGy in 33
fractions, and second for the third primary lower gingiva
tumor and left neck lymphadenopathy with 6000 cGy in 30
fractions. The accumulated dose to the right carotid artery
was 8932 cGy. Fourth, primary carcinoma of the right
zygomatic region was found in July 2017, but previous high-
dose radiotherapy made it impossible for the patient to
repeat further irradiation. He was then administered for
salvage BNCT treatment. The first BNCT treatment was
performed in September 2017. PET images three months
after the BNCT showed marked regression of the tumor.
Recurrent tumors were identified over the right tongue and
oropharyngeal region in 2019. A second BNCT was then
performed in May 2019. The dosage to the carotid artery
through the 2 courses of BNCT was 6.69 GyE (Gray equiva-
lent) and 6.79 GyE, respectively. Using an alpha to beta
ratio of 3, the equivalent dose to 2 Gy per fraction (EQD2)
was roughly 12.97 Gy and 13.29 Gy. This resulted in a total
dose of over 11,550 cGy to the carotid artery. With the highTable 1 Patient characteristics.
Patient No. Age Gender Primary d
1 54 M Buccal
2 52 M Right zygo
2 52 M Right zygo
3 74 M Hypophar
4 52 M Supraglott
M: Male, SqCC: squamous cell carcinoma, OP: operation, CCRT: concur
oral laser microsurgery, IT: immune therapy.
4
accumulated dosage to the carotid artery, the patient un-
derwent bimonthly CTA for carotid artery evaluation.
Impending CBS was noticed in November 2019, and embo-
lization was performed to prevent further progression of
CBS. Tri-monthly CTA was continued to evaluate carotid
artery patency and tumor response to BNCT. On the date of
the last follow-up in June 2020, CTA revealed that the
tumor was in stable control, and 40% in-stent and proximal
marginal restenosis was revealed.
The median age of the patients receiving BNCT for
recurrent head and neck cancer was 58 years (range, 52e74
years). The medium tumor to blood ratio (TB ratio) was 4.01
(range, 2.67.5.2), including the six tumors irradiated in 4
patients). The medium tumor to normal tissue ratio (TN
ratio) was 4.14 (range, 2.78e6.85) (Table 2). The medium
dose to the tumor by previous external beam therapy was
8299 cGy (range 6600 to 12,600 cGy), with one patient
receiving 2 courses of radiotherapy prior to BNCT. The
mean dose to the carotid artery by external beam radio-
therapy was 7390 cGy (range 6205e8932 cGy), including one
patient receiving 2 courses of radiotherapy, and one patient
not being able to be evaluated because they had received
their previous treatment at another hospital (Table 3). The
mean percentage of tumor encasement to the carotid ar-
tery was 63.75% (range 0%e100%), and 3 out of 4 patients
developed CBS after BNCT. The mean interval from the
previous radiotherapy to BNCT was 20.6 months (range,
6e35 months) for 5 BNCT treatments. The mean average
BNCT dose to the primary tumor was 24.22 Gy-E (range
15.14e32.01 Gy-E) for 6 irradiated sites. The mean
maximum dose to the carotid artery by BNCT was 7.22 Gy-E
(range 6.69e7.7 Gy-E). Patients 1 and 2 received interven-
tion after BNCT as vascular imaging showed impending CBS
(Fig. 2), while for patients 3 and 4, interventions for the
prevention of CBS before BNCT were done (Fig. 3).
Discussion
In March 2017, Taipei Veterans General Hospital triggered a
partnership with the Nuclear Science and Technology
Development Center of the National Tsing-Hua University.
Since there was increasing interest in BNCT worldwide
during that time, Taiwanese radiation oncology specialists
clinched the opportunity to collaborate with Japanese cli-
nicians and researchers, since Japan is the most experi-
enced country not only by case numbers but also in
conducting several basic studies about BNCT. As thermal
neutrons and epithermal neutron beams are necessary iniagnosis Histology Previous treatment
SqCC OP þ CCRT
matic SqCC OP þ CCRT
matic SqCC OP þ CCRT
yngeal SqCC IC þ CCRT þ TLM þ IT
ic SqCC OP þ IC þ CCRT þ IT
rent chemoradiotherapy, IC: induction chemotherapy, TLM: trans-
Figure 2 (Left upper) Image study showed huge necrotic tumor in the right maxillary sinus and right masticator space. (Right
upper) Contouring of the right internal carotid artery (Yellow), right external carotid artery (Orange), and right internal maxillary
artery (Red). Showing previous high dose irradiated to the right internal maxillary artery and risk of carotid blowout syndrome
(CBS). (Lower) Embolization procedure showed damaged right internal maxillary artery. Active vascular extravasation was noticed.
15% N-butyl cyanoacrylate (NBCA) mixture was injected for occlusion of the branch of internal maxillary artery.
Table 2 BNCT parameters and previous radiotherapy summary.
Patient No. TN ratio TB ratio RT dose to
primary (cGy)
RT end date BNCT date BNCT dose to primary
tumor (Dmean) (Gy-w)





6600 þ 6000a 20120228/20161014a 20170922 R31.62/L32.01
2 6.85 5.63 6600 þ 6000a 20120228/20161014a 20190506 15.14
3 3.04 3.25 7000 20160519 20190426 17.82
4 2.78 2.67 6996 20180423 20191225 19.62
BNCT: boron neutron capture therapy, TN ratio: tumor to normal tissue ratio, TB ratio: tumor to blood ratio, RT: radiotherapy, R: right
side, L: left side, Dmean: mean dose, Gy-w: total weighted dose.
a Patient 2 received 2 courses of radiotherapy both in the buccal region.
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reactor (THOR) was regarded as a perfect source of neutron
irradiation. As of November 2020, with the collaboration of
TPEVGH and THOR, more than 170 patients have received
BNCT in Taiwan.
BNCT has recently gained attention in salvage treatment
for recurrent head, neck, and brain tumors.12,13 In Japan,
BNCT has been approved as a standard treatment modality5
and has been included in the national health insurance
since May 2020. More and more BNCT specialist hospitals
were built and are constantly leading development both in
the number of patients treated and in basic research
studies. The advantage of using BNCT as a salvage treat-
ment is its binary feature. As the tumor has a higher uptake
of the boron-containing drug compared to normal organs,
BNCT is the ideal “targeted radiotherapy” that can be
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2 0% impending Embolization of
right ECA, stent on
right ICA/CCA
2019/12/11







2 0% impending Embolization of
right ECA, stent on
right ICA/CCA
2019/12/11
























CBS: carotid blowout syndrome, ECA: external carotid artery, ICA internal carotid artery, CCA: common carotid artery, N/A: not
applicable.
a Dose to carotid artery was not directly calculated during the first course of BNCT, and we estimated by using the TB ratio and
calculated from the dose to primary tumor.









1 20190616 Yes 10.43
2 Alive N/A 36
2 Alive N/A 16.47
3 Alive N/A 5.6
4 Alive N/A 8.4
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+ MODELexecuted even with the previous treatment causing damage
to the organs alongside. Since the treatment benefit is
based on the concentration gradient between the tumor
and the normal tissue, the development of boron-
containing drugs is what BNCT researchers are focusing on.
While BNCT is ushering in the new radiotherapy era,
complications caused by BNCT should also be taken into
serious consideration. Carotid blowout syndrome, usually
related to previous surgery or radiotherapy, is a fatal
adverse effect that was not so infrequent from our expe-
rience. The rationale for developing CBS includes stripping
of the carotid sheath during neck dissection, or radiation-
induced free radical damage to the adventitial layer of the
carotid artery.10 The adventitial layer comprises approxi-
mately 80% of the blood supply to the walls of the carotid
artery, and injuries to it may cause pseudoaneurysm for-
mation or necrosis of the arterial wall. Even though CBS
may not occur during the treatment duration, aggressive
treatments are usually the leading cause of the event.6
The importance of this review is that carotid artery
evaluation was not regularly conducted before BNCT in
most institutes. Previous Japanese studies have found that
the incidence rate of CBS in patients who receive BNCT of
the head and neck region is about 5%.14,15 In a systemic
review involving 27 published articles and more than 1500
patients with salvage re-irradiation for head and neck
cancers, an incidence rate of 2.6% was reported, with 76%
of the CBS episodes being fatal.4 A multi-institutional study
in Japan surveyed 72 patients with recurrent head and neck
cancers with hypo-fractionated stereotactic body radio-
therapy. 12 patients developed CBS (16.7%).16 In this
article, it was concluded that all of the patients who
developed CBS had tumor invasion to the carotid artery of
more than 180 degrees of the circumference. This finding is
very useful when classifying the risk of CBS and the ne-
cessity for prevention. Of the 4 patients we reported with
recurrent head and neck cancers receiving BNCT, 1 patient
with total invasion of the carotid artery without carotid
artery evaluation before BNCT developed CBS, and further
embolization was not sufficient to cease disease progres-
sion, which eventually resulted in fatal carotid hemor-
rhage. Two patients received preventive embolization
before BNCT treatment, and both were able to avoid life-
threatening CBS. Based on our experience, we suggest
that it is important to perform carotid artery evaluation
before BNCT treatment.
In our institute, as we had the experience of CBS in the
past, consultation for carotid artery evaluation before BNCT
will be conducted routinely, and intervention should be ar-
ranged if the patient is at risk of developing CBS.17,18 In our
Figure 3 Contrast enhanced computed tomography (CT) image and post stent insertion contrast enhanced CT image of patient 3.
(A) Tumor encasement of right carotid artery, high risk of CBS if aggressive treatment is planned. (B) Sagittal view of CT image after
stent graft was successfully inserted. (C) Axial view showing the image after stent insertion.
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impending CBS due to damaged vasculature or pseudoa-
neurysms were accidentally revealed. Early embolization
was then performed when the risk was still tolerable, and
thus the patient had the chance of receiving BNCT in a more
comfortable disease status. Although no huge data can be
shown to prove the exact benefit of pre-BNCT carotid artery
evaluation, we can potentially upregulate the limitation
dose of the ipsilateral carotid artery and push the dose to the
primary tumor to a higher level. This way, we can likely
contribute to a higher response rate.
BNCT is a new modality for salvage treatment of recur-
rent head and neck cancers. However, CBS is a devastating
adverse effect. Its risk is increased among patients who
have previously undergone surgery or received radio-
therapy as well as chemotherapy. We emphasize the
importance of performing pre-BNCT carotid artery evalua-
tion through CTA and early intervention if necessary. This
may result in not only improved treatment safety but also
higher dose tolerance to the treated area.References
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